N/A N=50 Improving Patient-Provider Communication to Reduce Mental Health Disparities
Healthcare Disparities · Mental Health
Primary: Patient Activation Measure- Mental Health (PAM-MH) — 5.7; 9.1 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=84 Improving Mind/Body Health and Functioning With Integrative Exercise
Stress Disorders, Post-Traumatic
Primary: Clinician Administered PTSD Scale (CAPS) Score Comparison Between Subjects Randomized to Integrative Exercise Treatment vs. Illness Management and Recovery — 24.4; 22.0…
N/A N=28 Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
Covid19
Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds
Phase 3 N=300 A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
Asthma
Primary: Rate of Clinically Significant Exacerbations of Asthma — 0.45; 1.31 Exacerbations per year — p=<0.001
Phase 4 N=313 Varenicline OTC Trial on Efficacy and Safety
Tobacco Dependence · Withdrawal Symptoms · Smoking Cessation
Primary: The Number of Participants Who Have Continuous Abstinence as Verified by Breath Carbon Monoxide or Urine Cotinine — 17; 9; 9 Participants
N/A N=47 Clinical Safety and Performance of GATT-Patch in Open Liver Surgery
Hemorrhage, Surgical
Primary: Hemostasis — 38; 46 Participants
N/A N=150 Dietary Carbohydrate and GERD in Veterans
Gastroesophageal Reflux Disease · Obesity
Primary: Gastroesophageal pH — 7.3; 6.6; 3.7; 4.9 percent time ph < 4 in 24 hrs
N/A N=15 (YMP) Young Moms Program
Chronic Toxic Stress · Developmental/ Behavioral Regression in Young Children
Primary: Protective Factors Survey Score — 104.7; 98 score on a scale
Phase 2 N=135 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Breast Cancer
Primary: Two-year Disease Free Survival — 54.2; 64.1 percentage of participants
N/A N=20 Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction
Restless Legs Syndrome
Primary: Percentage of Subjects Without a Clinically Significant Increase in RLS Symptoms During the First Phase Involving an Opioid Dose Reduction of >= 20% Relative to…
N/A N=11 Do Rocker Bottom Shoes and Ankle-Foot Orthoses Reduce Pain and Improve Mobility for Ankle Osteoarthritis Patients
Ankle Osteoarthritis · Healthy Ankles
Primary: Daily Step Count (# Steps) — 3453; 2399; 3453; 2745 steps
Phase 2 N=7 A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Malignant Melanoma
Primary: Tolerability Evaluated by NCI CTCAE v5.0 — 52; 130; 6; 11 Number of Events
N/A N=140 Noradrenergic Activity and Attention
Aging
Primary: Initial Eye-movements Toward Target and Distractor Shapes Measured by an Eye-tracker — 3.8; 4.4; 3.6; 4.5 percentage of first saccades
N/A N=500 Brevera™ Breast Biopsy System Data Collection Study
Breast Cancer Female
Primary: Procedural Time — 38.44 Minutes
Phase 2 N=6 CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)
Radiculopathy
Primary: Change in Opioid Analgesic Plasma Levels — 10.86; -11.4 ng/mL